+

WO2003003011A1 - Modification de l'angiogenese par ciblage de proteines tyrosines phosphatases - Google Patents

Modification de l'angiogenese par ciblage de proteines tyrosines phosphatases Download PDF

Info

Publication number
WO2003003011A1
WO2003003011A1 PCT/AU2002/000848 AU0200848W WO03003011A1 WO 2003003011 A1 WO2003003011 A1 WO 2003003011A1 AU 0200848 W AU0200848 W AU 0200848W WO 03003011 A1 WO03003011 A1 WO 03003011A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
aryl
ptp
angiogenesis
Prior art date
Application number
PCT/AU2002/000848
Other languages
English (en)
Inventor
Philip John Hogg
Original Assignee
Unisearch Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unisearch Limited filed Critical Unisearch Limited
Publication of WO2003003011A1 publication Critical patent/WO2003003011A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to methods for screening chemical compounds to identify a compound which modifies angiogenesis through its interaction with at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • the invention relates to the use of the compounds so identified, and compositions containing same in the modification of these protein tyrosine phosphatases and the subsequent modification of angiogenesis, in particular the inhibition of angiogenesis.
  • the invention relates to methods of treating angiogenic dependent disease via the use of compounds capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of; PTP-PEST and PTP-1 B.
  • angiogenesis The sprouting of new capillaries from existing vessels is termed angiogenesis, and occurs during embryogenesis and in the adult. In the normal adult mammal angiogenesis is confined to the female reproductive cycles, wound healing and several pathological situations. Angiogenesis is a key factor in diseases such as rheumatoid arthritis, psoriasis, diabetic retinopathy and cancer.
  • Angiogenesis is controlled by the balance between proliferative/anti-apoptotic factors such as vascular endothelial cell and fibroblast growth factors and anti-proliferative/pro-apoptotic factors such as thrombospondin, angiostatin and endostatin.
  • proliferative/anti-apoptotic factors such as vascular endothelial cell and fibroblast growth factors
  • anti-proliferative/pro-apoptotic factors such as thrombospondin, angiostatin and endostatin.
  • the basement membrane surrounding an endothelial cell tube is locally degraded, which triggers the endothelial cells underlying this disrupted matrix to change shape and invade the surrounding tumor stroma.
  • the invading endothelial cells proliferate and develop into a migrating column.
  • the cells of the column wall stop proliferating, change shape, and adhere to each other to form the lumen of the new capillary.
  • the new capillaries fuse and form into loops, resulting in a circulatory system that facilitates exchange of nutrients and waste products in the region.
  • the present invention resides in the discovery that the modification in activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B has a modifying effect upon angiogenesis, particularly in proliferating endothelial cells.
  • PTP-PEST protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B has a modifying effect upon angiogenesis, particularly in proliferating endothelial cells.
  • the present invention provides a method of screening a plurality of candidate compounds to identify a compound which modifies at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • the present invention provides a method for modifying at least one such protein tyrosine phosphatase in a vertebrate, and thereby modifying angiogenesis, wherein said method comprises administering to the s vertebrate a therapeutically effective amount of at least one of the compounds identified by the screening method or at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound.
  • a process for identifying a o compound which is a modifier of angiogenesis comprising contacting a cell or cell extract with a candidate compound, determining whether there is a change in the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and thereby determining whether the compound is a modifier of angiogenesis.
  • a process for 5 screening a plurality of compounds to identify a compound which is a modifier of angiogenesis comprises contacting a cell or a cell extract with said plurality of compounds, determining whether there is a change in the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and if so, separately determining the change in activity of said protein tyrosine phosphatase for each of the plurality of compounds, o thereby determining the identity of the compound which is a modifier of angiogenesis.
  • the protein tyrosine phosphatase is PTP-PEST. More typically, the protein tyrosine phosphatase is PTP-1 B.
  • the cell is a mammalian cell. More typically, the cell is selected from the group consisting of: endothelial cells, epithelial cells, immune cells, bone, bone marrow cells and tumour cells. Even more typically, the cell is selected from the group consisting of: proliferating endothelial cells.
  • the process in accordance with the first or second embodiments of the invention comprises contacting a cell extract.
  • the compounds screened in accordance with the first or second embodiments of the invention are compounds that are not previously known to modify angiogenesis.
  • a method of inhibiting at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B in a vertebrate comprises administering to the vertebrate a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention for the manufacture of a medicament for inhibiting at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B in a vertebrate.
  • a method of stimulating at least one protein tyrosine phosphatase selected from the group consisting of: PTP- PEST and PTP-1 B in a vertebrate comprises administering to the vertebrate a therapeutically effective amount of at least one modifier detected in accordance with the process of the fourth embodiment of the present invention, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • an eighth embodiment of the invention there is provided use of a therapeutically effective amount of at least one modifier detected in accordance with the process of the fourth embodiment of the present invention for the manufacture of a medicament for stimulating at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B in a vertebrate.
  • a method of inhibiting angiogenesis in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention for the manufacture of a medicament for inhibiting angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • a method of stimulating angiogenesis in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP- 1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier detected in accordance with the process of the fourth embodiment of the present invention, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a therapeutically effective amount of at least one modifier detected in accordance with the process of the fourth embodiment of the present invention for the manufacture of a medicament for stimulating angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • a method of treating an angiogenesis dependent disease in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP- PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a fourteenth embodiment of the invention there is provided use of a therapeutically effective amount of at least one modifier detected in accordance with the process of the third embodiment of the present invention for the manufacture of a medicament for treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP- PEST and PTP-1 B.
  • a method of modifying angiogenesis in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering to the vertebrate a therapeutically effective amount of an compound capable of changing the activity of at least one of said protein tyrosine phosphatases.
  • a therapeutically effective amount of an compound capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B for the manufacture of a medicament for modifying angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • angiogenesis is inhibited or stimulated. More typically, the activity of said protein tyrosine phosphatase is inhibited or stimulated.
  • a method of treating an angiogenesis dependent disease in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering a therapeutically effective amount of at least one compound capable of inhibiting the activity of at least one of said protein tyrosine phosphatases.
  • a therapeutically effective amount of at least one compound capable of inhibiting the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP- 1 B for the manufacture of a medicament for treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • a method of treating an angiogenesis dependent disease in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering a therapeutically effective amount of at least one compound capable of stimulating the activity of at least one of said protein tyrosine phosphatases.
  • a therapeutically effective amount of at least one compound capable of stimulating the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP- 1 B for the manufacture of a medicament for treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • a method of inhibiting angiogenesis in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP- 1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound.
  • a therapeutically effective amount of at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound for the manufacture of a medicament for inhibiting angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • a method of treating an angiogenesis dependent disease in a vertebrate wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound.
  • a twenty-fourth embodiment of the invention there is provided use of at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound for the manufacture of a medicament for treating an angiogenesis dependent disease, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase in a vertebrate in a vertebrate.
  • the vertebrate is one in need of said modification, inhibition or treatment.
  • the substantially cell-membrane impermeable compound typically targets rapidly proliferating endothelial cells and is of the formula (I): wherein
  • A comprises at least one substantially cell-membrane impermeable pendant group;
  • L comprises any suitable linker and/or spacer group;
  • Y comprises at least one arsenoxide or arsenoxide equivalent;
  • p is an integer from 1 to 10.
  • A is selected from the group consisting of natural, unnatural and synthetic amino acids, hydrophilic amines, peptides, polypeptides, oligosaccharides, and thiol containing proteins, or a combination thereof.
  • A is selected from the group consisting of glutathione, glucosamine, cysteinylglycine, cysteic acid, aspartic acid, glutamic acid, lysine, and arginine, and wherein the sulfur atom of each sulfur containing compound may be optionally oxidised to form a sulfoxide or sulfone.
  • Amino acid side chains are known to those of skill in the art and are listed, for example, in standard reference texts such as King and Stansfield, "A Dictionary of Genetics", 4 th Edition, Oxford University Press, 1990, the contents of which are incorporated herein by reference.
  • A is glutathione and in one form the substantially cell-membrane impermeable compound suitable for use in the present invention is represented by Formula (II):
  • L comprises any suitable linker and/or spacer group
  • Y comprises an arsenoxide or an arsenoxide equivalent.
  • p is an integer from 1 to 5. Yet still more typically, p is 1.
  • L corresponds to (XBX')nB'.
  • n is an integer from 0 to 20, more typically 0 to 15, even more typically 0 to 10, still more typically 0 to 5.
  • X is selected from the group consisting of -NR, -S(O)-, -S(O)0-, -S(0) -, -S(0) 2 0-, -C(O)-, -C(S)-, -C(O)0-, C(S)0-, -C(S)S-, -P(0)(R ⁇ )-, and -P(0)(R ⁇ )0-, or is absent;
  • B is selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, C5-C10 cycloalkenylene, C3-C10 heterocycloalkylene, C5-C10 heterocycloalkenylene, C6-C12 arylene, heteroarylene and C2-C10 acyl;
  • X 1 is selected from the group consisting of -NR-, -0-, -S-, -Se-, -S-S-, S(O)-, -OS(O)-, OS(0)0-, -OS(0) 2 , -OS(0) 2 0-, -S(0)0-, -S(0) 2 -, -S(0) 2 0-, -OP(O)(R ⁇ )-, -OP(0)(R ⁇ )0-,
  • R ' R ' or is absent; wherein E is 0, S, Se, NR or N(R) 2 + ; n is 0, 1 or 2; and
  • B' is selected from the group consisting of C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene, C3-C10 cycloalkylene, C5-C10 cycloalkenylene, C3-C10 heterocycloalkylene, C5-C10 heterocycloalkenylene, C6-C12 arylene, and heteroarylene or is absent; and wherein each R is independently selected from the group consisting of hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C3-C10 heterocycloalkyl, C5-C10 heterocycloalkenyl, C6-C12 aryl, heteroaryl, OR2 and C2-C10 acyl;
  • R' is the same as R or two R' may be taken together with the nitrogen atoms to which they are attached to form a 5 or 6-membered saturated or unsaturated heterocyclic ring; each Ri is independently selected from the group consisting of hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C3-C10 heterocycloalkyl, C5- C10 heterocycloalkenyl, C 6 -Ci2 aryl, heteroaryl, halo, OR2 and N(R) 2 ; each R 2 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C3-C10 heterocycloalkyl, C5-C10 heterocyclo
  • R, Ri and R5 are as defined above;
  • R2a is selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C 6 -C ⁇ 2 aryl, -S(0)R , -S(0) 2 R3, -P(0)(R 4 )2, N(R) 2 and -C(0)R 5 ; each R3 is independently selected from the group consisting of hydrogen, C1-C10 alkyl, C2- C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C3-C10 heterocycloalkyl, C5-C10 heterocycloalkenyl, C6-C12 aryl, heteroaryl, C1-C10 alkoxy, C3-C10 alkenyloxy, C3-C10 alkynyloxy, C3
  • R" is the same as R or two R" taken together with the N atom to which they are attached may form a saturated, unsaturated or aromatic heterocyclic ring system;
  • Q is selected from halogen and -OS(0)2Q ⁇ ; wherein Q1 is selected from C1-C4 alkyl, C1-C4 perfluoroalkyl, phenyl, p-methylphenyl; and m is 1 to 5.
  • X is selected from the group consisting of -C(O)-, -C(S)-, -C(0)0-, C(S)0-, and -C(S)S-, or is absent;
  • B is selected from the group consisting of C1-C5 alkylene, C2-C5 alkenylene, C2-C5 alkynylene, C3-C10 cycloalkylene, C5-C10 cycloalkenylene, C6-C12 arylene and C2-C5 acyl;
  • X is selected from the group consisting of -0-, -S-, -NR-, -S-S-, -S(O)-, -S(0) -, -P(0)(R ⁇ )-, -
  • E is 0, S or N(R)2 + ; n is O, 1 or 2; and
  • B' is C1-C5 selected from the group consisting of alkylene, C2-C5 alkenylene, C2-C5 alkynylene, ' C3-C10 cycloalkylene, C5-C10 cycloalkenylene, and C6-C12 arylene, or is absent; and wherein each R is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, OR2 and C2-C10 acyl;
  • R' is the same as R; each Ri is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, halo, OR2 and N(R)2i each R2 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, and -C(0)Rs; each R5 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 ary
  • R 2a is selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C 6 -C ⁇ 2 aryl, -S(0)R 3 , -S(0) 2 R3, -P(0)(R ) , N(R) 2 and -C(0)R 5 ; each R3 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, C1-C5 alkoxy, C3-C5 alkenyloxy, C3-C5 alkynyloxy, C3-C10 cycloalkyloxy, C5-C10 cycloalkenyloxy, C6-
  • R ⁇ is independently selected from the group consisting of C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, C1-C5 alkylthio, C3-C5 alkenylthio, C3-C5 alkynylthio, C3-C10 cycloalkylthio, C5-C10 cycloalkenylthio, C6-C12 arylthio, -S(0)R3, -S(0)2R3 and - C(0)R 5 , R" is the same as R;
  • Q is selected from the group consisting of halogen and -OS(O)2Q ⁇ ; wherein Q1 is selected from C1-C4 alkyl, C1-C4 perfluoroalkyl, phenyl, p-methylphenyl; and m is 1 to 5.
  • B is selected from the group consisting of C1-C5 alkylene, C6-C12 arylene and C2-C5 acyl;
  • X is selected from the group consisting of -O-, -S-, -NR-, -S-S-, -S(O)-, -S(0) 2 -, -P(0)(R ⁇ )-, - C(O)-, -C(S)-, -C(0)0-, C(S)0-, -Se-, and E
  • R R ' or absent; wherein E is 0, S or N(R)2 + ; n is O, 1 or 2; and
  • B' is C1-C5 alkylene, C6-C12 arylene or is absent; and wherein each R is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl, OR2 and C2-C5 acyl; R' is the same as R; each Ri is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl, halo, OR2 and N(R) 2 ; each R 2 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl and -C(0)Rs; each R5 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl,
  • R, Ri and R5 are as defined above; and R2a is selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl, -S(0)R 3 , -S(0) 2 R 3 , -P(0)(R 4 ) 2 and -C(0)R 5 ; each R3 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl, C1-C5 alkoxy, C3-C10 cycloalkyloxy, C6-C12 aryloxy, C1-C5 alkylthio, C3-C10 cycloalkylthio, C6-C12 arylthio and N(R)2; each R4 is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C3-C10 cycloalkyl, C0-C12 aryl, C
  • Re is selected from the group consisting of C1-C5 alkyl, C3-C10 cycloalkyl, C6-C12 aryl, C1-C5 alkylthio, C3-C10 cycloalkylthio, C6-C12 arylthio, -S(0)R 3 , -S(0) R3 and -C(0)R 5
  • Q is selected from halogen and -OS(0)2Q ⁇ ; wherein Q1 is selected from C1-C4 alkyl, C1-C4 perfluoroalkyl, phenyl, p-methylphenyl; and m is 1 to 5.
  • X is absent;
  • B is selected from the group consisting of C1-C5 alkylene, C6-C12 arylene and C2-C5 acyl;
  • X is selected from the group consisting of-O-, -S-, -NR-, -C(O)-, and -C(0)0-, or is absent; n is 1 ; and
  • B' is C1-C5 alkylene, C6-C12 arylene or is absent;
  • R is selected from the group consisting of hydrogen, C1-C5 alkyl, C6-C12 aryl and C2-C5 acyl; wherein for each instance that B and/or B' is arylene, the substituents directly attached to the respective arylene rings (including arsenoxide or arsenoxide equivalent), may be in a para-, meta- or ortho- relationship, and wherein each alkylene, arylene, and acyl may be independently substituted with hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, C3-C10 cycloalkyl, C5-C10 cycloalkenyl, C6-C12 aryl, halo, cyano, cyanate, isocyanate, OR ⁇ a, SR ⁇ , nitro, arsenoxide, -S(0)R3, -S(0)2R3, -P(0)R4R4, -N(R")2, - NRC(0)(CH 2
  • each R is independently selected from the group consisting of hydrogen, C1-C5 alkyl, C6-C12 aryl and C2-C5 acyl; R ⁇ a is selected from the group consisting of hydrogen, C1-C5 alkyl, C6-C12 aryl, -S(O)R3, -
  • R ⁇ is selected from the group consisting of C1-C5 alkyl, C6-C12 aryl, C1-C5 alkylthio, C6-C12 arylthio, -S(0)R 3 , -S(0) 2 R 3 and -C(0)R 5 ,
  • R" is the same as R above;
  • Q is selected from halogen and -0S(0)2Q ⁇ ; wherein Q-i is selected from C1-C4 alkyl, C1-C4 perfluoroalkyl, phenyl, p-methylphenyl; and m is 1 to 5.
  • X is absent
  • B is C2-C5 acyl; X' is NR; n is 1 ;
  • B' is phenylene
  • R is H; wherein the substituents directly attached to the phenylene ring may be in a para-, meta- or ortho- relationship, as
  • R7 to R10 are independently selected from the group consisting of hydrogen, C1-C5 alkyl, C6-C12 aryl, halogen, hydroxy, amino, nitro, carboxy, C1-C5 alkoxy, -0S(0)2R3 and - NHC(0)CH 2 Q wherein Q is halogen, -0S(0) 2 CH3, -OS(0) 2 C 6 H 5 and -0S(0) 2 -p tolyl; and wherein, when any one of R7 to R10 is C1-C5 alkyl, C6-C12 aryl, C1-C5 alkoxy, -OS(0) 2 R3 it is capable of forming a fused ring with the phenylene; and further wherein, at least one of R 7 to Rio is C1-C5 alkyl, C ⁇ -C ⁇ 2 aryl, C1-C5 alkoxy, or -OS(0) 2 R3, in combination with at least any one other of R 7 to R10, is capable of forming a
  • R7 to R10 are independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, carboxy, C1-C5 alkoxy, methyl, ethyl, isopropyl, tert-butyl, phenyl and -NHC(0)CH Q wherein Q is halogen, -OS(0) CH 3 , -OS(0)2C 6 H 5 and -OS(0) 2 -p tolyl.
  • a substantially cell-membrane impermeable arsenoxide compound suitable for use in the present invention is 4-(A/-(S-glutathionylacetyl)amino)-phenylarsenoxide, which can be abbreviated to GSAO, according to Formula IV:
  • substantially cell membrane impermeable arsenoxide compounds suitable for use in the present invention include compounds according to Formula (V):
  • the invention provides the compounds 3-( ⁇ /- (fluoroacetyl)amino)-4-(A/-(S-glutathionylacetyl)amino)phenylarsenoxide, which may be abbreviated to GSFAO, 3-(A/-(chloroacetyl)amino)-4-(A/-(S-glutathionylacetyl)amino)phenylarsenoxide, which may be abbreviated to GSCAO, 3-(A/-(bromoacetyl)amino)-4-(A/-(S-glutathionylacetyl)amino)- phenylarsenoxide, which may be abbreviated to GSBAO, and 3-(A/-(iodoacetyl)amino)-4-(A/-(S- glutathionylacetyl)amino)phenylarsen
  • G is selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, carboxy, C1-C5 alkoxy, C1-C5 alkyl and C6-C ⁇ 2 aryl and -NHC(0)CH 2 Q, wherein Q is halogen, -OS(0) 2 CH , -OS(0) 2 C 6 H 5 or -OS(0) 2 -p tolyl.
  • G is selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, carboxy, C1-C5 alkoxy, methyl, ethyl, iso-propyl, tert-butyl, phenyl, and -NHC(0)CH 2 Q, wherein Q is the group consisting of halogen, -OS(0) 2 CH3, -OS(0) 2 C6Hs and -OS(0) 2 -p tolyl. More typically, in a compound of Formula VI, G is hydroxy, fluorine, amino, or nitro.
  • group G is in an ortho-, meta- or para- relationship to the arsenoxide group, more typically an ortho- or para- relationship.
  • the activity of the arsenic atom may be modified by the group G, when G and the arsenic atom are in an ortho or para relationship to one another.
  • G is an electron donating group such as OH (ionised to 0- at physiological pH)
  • the arsenic atom should be deactivated towards dithiols and so become more selective, only reacting with very reactive dithiols.
  • G is an electron withdrawing group, such as N0 2
  • electron density would be drawn away from the arsenic atom, making it more reactive to all dithiols. Selective inhibition of some redox proteins and not others may be achieved by manipulation of G.
  • arsenoxide equivalent includes dithiol reactive entities, such as As, Ge, Sn and Sb species. More typically an arsenoxide equivalent can be represented by -D(Z ⁇ )(Z 2 ).
  • Arsenoxide equivalents are expected to exhibit identical or substantially identical activity to that of the corresponding arsenoxide.
  • D will be, for example, As RSn, Sb, or RGe
  • Z1 and Z 2 will be labile groups (i.e. groups easily displaced under physiological conditions).
  • Zi and Z 2 may be identical or different, and may either be connected or independent from each other (bound only to the arsenic atom).
  • Suitable arsenoxide equivalents include the following:
  • Zi and Z2 are selected from the group consisting of OH, C1-C10 alkoxy, C ⁇ -Cio aryloxy, C1- C10 alkylthio, C ⁇ -C-IO arylthio, C1-C10 alkylseleno, C6-C10 arylseleno, F, Cl, Br and I;
  • arsenoxide equivalents of the form D(Z ⁇ )(Z 2 ) when D is As and Z-i and Z 2 are OH, the arsenoxide equivalent may be in equilibrium with polymeric species, as depicted below.
  • the dehydration reaction is reversible, and therefore soluble polymeric anhydrides are expected to behave as arsenoxide equivalents, that is, they are expected to bind to closely spaced dithiols in substantially the same way as the monomeric -As(OH) 2 species.
  • R' is selected from the group consisting of hydrogen, C1-C10 alkyl, C6-C12 aryl, and carboxy, or is one of the twenty amino acid side chains;
  • R11 to Ri4 are selected from the group consisting of hydrogen, C1-C10 alkyl, C6-C12 aryl, and
  • Rn to R14 are selected from the group consisting of hydrogen, C1-C10 alkyl, C6-C12 aryl, halogen, C1-C10 alkoxy, and CO2H.
  • (XBX')B' is as defined above,
  • arsenical as used herein, includes any compound that contains arsenic.
  • acyl as used herein, includes monovalent and divalent alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl moieties possessing a terminal carbonyl substituent wherein attachment may occur at the hydrocarbon moiety, the carbonyl moiety or both.
  • alkyl as used herein, includes within its meaning monovalent, saturated, straight and branched chain hydrocarbon radicals.
  • alkenyl as used herein, includes within its meaning, monovalent, straight and branched chain hydrocarbon radicals having at least one double bond.
  • alkynyl as used herein, includes within its meaning, monovalent, straight and branched chain hydrocarbon radicals having at least one triple bond.
  • alkylene as used herein, includes within its meaning divalent, saturated, straight chain hydrocarbon radicals.
  • alkenylene as used herein, includes within its meaning, divalent, straight chain hydrocarbon radicals having at least one double bond.
  • alkynylene as used herein, includes within its meaning, divalent, straight chain hydrocarbon radicals having at least one triple bond.
  • aryl as used herein, includes within its meaning monovalent, single, polynuclear, conjugated and fused aromatic hydrocarbon radicals.
  • arylene as used herein, includes within its meaning divalent, single, polynuclear, conjugated and fused aromatic hydrocarbon radicals
  • closed dithiol as used herein, includes within its meaning thiols that are chemically vicinal, as well as thiols brought into spacial apposition by virtue of molecular conformation.
  • cycloalkyl as used herein, includes within its meaning monovalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon radicals.
  • cycloalkylene as used herein, includes within its meaning divalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon radicals.
  • cycloalkenyl as used herein, includes within its meaning monovalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon radicals having at least one double bond.
  • cycloalkenylene as used herein, includes within its meaning divalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic hydrocarbon radicals having at least one double bond.
  • halo as used herein, includes fluoro, chloro, bromo and iodo.
  • heteroaryl as used herein, includes within its meaning monovalent, single, polynuclear, conjugated and fused aromatic radicals having 1 to 12 atoms wherein 1 to 6 atoms are heteroatoms selected from 0, N and S.
  • heteroarylene as used herein, includes within its meaning divalent, single, polynuclear, conjugated and fused aromatic radicals having 1 to 12 atoms wherein 1 to 6 atoms are heteroatoms selected from 0, N and S.
  • heterocycloalkyl as used herein, includes within its meaning monovalent, saturated, monocyclic, bicyclic, polycyclic or fused radicals wherein 1 to 5 atoms are heteroatoms selected from 0, N or S.
  • heterocycloalkylene includes within its meaning divalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic radicals wherein 1 to 5 atoms are heteroatoms selected from 0, N or S.
  • heterocycloalkenyl as used herein, includes within its meaning monovalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic radicals having at least 1 double bond and wherein 1 to 5 atoms are heteroatoms selected from 0, N or S.
  • heterocycloalkenylene as used herein, includes within its meaning divalent, saturated, monocyclic, bicyclic, polycyclic or fused polycyclic radicals having at least one double bond and wherein 1 to 5 atoms are heteroatoms selected from 0, N or S.
  • phenylarsonic acid as used herein, is to be considered synonymous with “benzene sulfonic acid”.
  • therapeutically effective amount includes within its meaning a non-toxic but sufficient amount a compound or composition for use in the invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate "effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
  • transition element includes within its meaning the groups of elements comprising the transition metals, the lanthanides and the actinides.
  • Abbreviations pAA p-arsanilic acid, 4-aminobenzenearsonic acid; AspAO, ⁇ /-(3-(4- arsenosophenylcarbamoylmethylthio)propanoyl)-L-aspartic acid; BAE, bovine aortic endothelial;
  • BCE bovine capillary endothelial
  • BCS bovine calf serum
  • BSA bovine serum albumin
  • BAE bovine aortic endothelial
  • BCE bovine capillary endothelial
  • BVSM bovine vascular smooth muscle
  • BRAA 4-( ⁇ /-(bromoacetyl)amino)phenylarsonic acid
  • BRAO 4-( ⁇ /-(bromoacetyl)amino)- phenylarsenoxide
  • BVS bovine vascular smooth muscle
  • CAM chick chorioallantoic membrane
  • Cys*AO A/-(3-(4-arsenosophenylcarbamoylmethylthio)propanoyl)-L-cysteic acid; DMEM,
  • Dulbecco's Modified Eagle's Medium DMP, 2,3-dimercaptopropanol
  • DMSO dimethylsulfoxide
  • DTNB 5,5'-dithiobis(2-nitrobenzoic acid); DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid; FAK, focal adhesion kinase; FAKpTyr, tyrosine phosphorylated FAK; GSCA, (4-(N-(S- glutathionylacetyl)amino)benzoic acid); FCS, fetal calf serum; FGF, fibroblast growth factor; GSAO- F, 4-(/V-(S-( ⁇ /-(3-(fluorescein-5- carbamoylmethylthio)propanoyl)glutathionyl)acetyl)amino)phenylarsenoxide; FXAO, a mixture of 4- ( ⁇ /-(6-(fluorescein-5-carboxamido)hexanoyl)amino)phenylarsenoxide and 4-( ⁇ /-(
  • 20,000 HMEC-1 per well were seeded into 96-well culture plates and allowed to attach for 24 h.
  • the media was then replaced with MCDB and 10% FCS containing either 100 or 10 ⁇ M MPB or DTNB and incubated for 5 min. 0, 100 or 250 ⁇ M GSAO was then added and the cells cultured for a further 24 h. The number of adherent cells was measured. The data points are the mean ⁇ SE of quadruplicate wells.
  • the media was then replaced with DMEM containing 5% BCS and 1 ng.m 1 FGF-2 and either 10 ⁇ M GSAO or GSAA.
  • Cells were cultured for discrete times up to 48 h and then dispersed and counted. The dotted line represents no change in cell number over the 48 h.
  • the data points are the mean + range of duplicate wells.
  • E Kinetics of uptake of GSAO. 500,000 HMEC-1 per well were seeded into 6-well culture plates and allowed to attach for 24 h.
  • the media was then replaced with MCDB-131 and 10% FCS containing 3 ⁇ M H-GSAO and the cells incubated for 24, 48 or 72 h.
  • a GSAO caused hyperphosphorylation of tyrosine residues in focal adhesion proteins in endothelial cells.
  • 80,000 HMEC-1 per well were seeded into 2-well Labtek glass chamber slides and allowed to attach for 24 h. The media was then replaced with MCDB-131 containing 10% FCS without or with 100 ⁇ M GSAO and the cells incubated for 10 h. The cells were washed and immunostained for phosphotyrosine.
  • B HMEC-1 were untreated (lane 1) or incubated with 100 ⁇ M GSAO for 8 h (lane 2), 10 ⁇ M GSAO for 24 (lane 3), 48 (lane 4) or 72 (lane 5) h or 1 ⁇ M PAO for 4 h (lane 6).
  • Cell lysate was prepared in the presence of 1 mM vanadate to block dephosphorylation and 25 ⁇ g resolved on 8-16% - SDS-PAGE, transferred to PVDF membrane and blotted for phosphotyrosine.
  • the extent of tyrosine phosphorylation of two proteins with molecular masses of -120 and -70 kDa was changed by incubation with GSAO (indicated by arrows).
  • C HMEC-1 were untreated or incubated with 100 ⁇ M GSAO for 8 h.
  • FAK or paxillin was immunoprecipitated from the cell lysates and blotted for phosphotyrosine. The membranes were stripped and reprobed for FAK or paxillin protein.
  • the relative increase in tyrosine phosphorylation of FAK or paxillin is shown by the bar graph.
  • D Phosphorylated FAK (FAKpTyr) was prepared in HMEC-1 by incubation with 10 ⁇ M PAO for 30 min and collected by immunoprecipitation. 50 ⁇ g of lysate from untreated HMEC-1 was incubated without or with 2 mM vanadate, 1 ⁇ M PAO or 0.1 , 2 or 40 ⁇ M GSAO for 10 min at 37°C.
  • FAKpTyr was then added to the lysates and incubated for 90 min at 37°C. Dephosphorylation of FAKpTyr was measured by blotting for phosphotyrosine.
  • Densitometric analysis of the blots is shown by the bar graph.
  • E HMEC-1 were incubated in the absence or presence of 100 ⁇ M GSAO for 8 h. Lysate was prepared from the untreated or treated cells and 50 ⁇ g incubated with FAKpTyr for 90 min at 37°C. Dephosphorylation of FAKpTyr was measured by blotting for phosphotyrosine. Densitometric analysis of the blots is shown by the bar graph.
  • F Lysate of HMEC-1 was incubated with 2 ⁇ M GSAO-biotin in the absence or presence of 1 mM DMP for 1 h at 4°C.
  • PTP-PEST, SHP2, PTEN or PTP-1 B was immunoprecipitated from the lysate and blotted with streptavidin-peroxidase to detect bound GSAO-biotin.
  • GSAO was a Selective Inhibitor of Endothelial Cell Proliferation and Viability
  • A-C 15,000 BCE (parts A and B) or BxPC-3 (part C) cells per well were seeded into 24-well culture plates and allowed to attach for 24 h. Gelatinized wells were used for BCE cells. The media was then replaced with DMEM containing 0 to 1 mM GSAO or GSAA and a mitogen. For BCE cells the mitogen was 5% BCS with either 1 ng.m 1 FGF-2 (part A) or 10 ng.mL- 1 VEGF (part B). For
  • BxPC-3 cells the mitogen was 5% FCS. Cells were cultured for 72 h and adherent cells were dispersed and counted. The dotted lines indicate the cell number in control wells containing DMEM and either 5% BCS (parts A and B) or 2% FCS (part C), which represented no to limited proliferation.
  • the data points are the mean ⁇ range of duplicate wells, D 20,000 BAE cells per well were seeded into 96-well culture plates and allowed to attach for 24 h, The cells were made growth quiescent by incubating with DMEM containing 0.25% FCS for 48 h. The medium was then replaced with DMEM containing either 0.25% or 10% FCS and either 50 ⁇ M GSAO or 0.5 ⁇ M PAO. Cells were cultured for a further 48 h and the number of adherent cells was measured. The data points are the mean ⁇ SE of quadruplicate wells.
  • Methylcellulose discs containing either GSAA or GSAO were applied to the CAM of individual embryos and incubated for 48 h. The number out of 5 zones positive for angiogenesis inhibition is shown in part A, GSAA did not inhibit CAM angiogenesis up to 50 ⁇ g per pellet. Photographs of CAM'S after incubation with discs containing 10 ⁇ g of either GSAA (top) or GSAO (bottom) is shown in part B. The dotted circle indicates the placement of the disc.
  • the compounds were administered S.C. at a site distant from the tumor. Tumor volume was measured as indicated.
  • the GSAO/GSAA tumor volume ratios at the conclusion of treatment were 0.34 (part A), 0.09 (part B), 0.29 (part C) and 0.29 (part D).
  • the data points are the mean ⁇ SE of the tumor volumes.
  • Mice drink -5 mL of water per day and therefore consumed -10 mg GSAO or GSCA/GSAA per kg per day.
  • the water contained 20 mM glycine to minimize oxidation of GSAO.
  • Tumor volume was measured as indicated. The data points are the mean ⁇ SE of the tumor volumes.
  • Figure 7. Schematic representation of the synthesis of GSAO-B
  • the present invention relates to a process of determining whether a compound is a modifier of angiogenesis, said process comprising contacting a cell or cell extract with said compound, determining whether there is a change in the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and thereby determining whether the compound is a modifier of angiogenesis.
  • the invention relates to a process for screening a plurality of compounds to identify a compound which is a modifier of angiogenesis, wherein said process comprises contacting a cell or a cell extract with said plurality of compounds, determining whether there is a change in the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and if so, separately determining the change in activity of said protein tyrosine phosphatase for each of the plurality of compounds, thereby determining the identity of the compound which is a modifier of angiogenesis.
  • a process for screening a plurality of compounds to identify a compound which is a modifier of angiogenesis comprises contacting a cell or a cell extract with said plurality of compounds, determining whether there is a change in the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and if so, separately determining the change in activity of
  • the cell is a mammalian cell. More typically, the cell is selected from the group consisting of: endothelial cells, epithelial cells, immune cells, bone and bone marrow cells and tumour cells. Even more typically, the cell is selected from the group consisting of: proliferating endothelial cells.
  • the compounds screened in the processes of the invention are those that are not previously known to inhibit a protein tyrosine phosphatase, and more typically, those that are not previously known to inhibit a protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B.
  • the invention relates to a method of inhibiting or stimulating angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier of angiogenesis as detected above, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with. a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • the invention is also concerned with a method of treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier of angiogenesis as detected above, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a pharmaceutically acceptable carrier, adjuvant and/or diluent comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • the invention also relates to a method of modifying angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering to the vertebrate a therapeutically effective amount of an compound capable of changing the activity of at least one of said protein tyrosine phosphatases.
  • the modification of angiogenesis can take the form of inhibition or stimulation. Further, the activity of said protein tyrosine phosphatase is inhibited or stimulated.
  • the invention relates to a method of treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering a therapeutically effective amount of at least one compound capable of inhibiting or stimulating the activity of at least one of said protein tyrosine phosphatases.
  • the compound referred to above comprises at least one substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compound.
  • substantially cell-membrane impermeable arsenoxide or arsenoxide equivalent compounds such as GSAO may be prepared by methods known generally in the art.
  • E represents an electrophilic site
  • m, n are integers greater than or equal to 0.
  • the scheme below shows a starting molecule RCH 2 X, where R represents the rest of the molecule to which the -CH 2 X group is attached.
  • X represents a leaving group, for example, a halogen or RSO3-, which is displaced by the nucleophile TR ⁇ .
  • Nucleophiles attack at electrophilic sites, resulting in the formation of a new covalent bond between the nucleophilic and electrophilic species.
  • the methylene carbon atom is the electrophilic site, and the overall reaction can be described as one of nucleophilic substitution.
  • reaction (i) to (iii) In all three reactions (i) to (iii), X is lost as X- and atom T must have a lone pair of electrons. Shown below are general examples of each of the reactions (i) to (iii). Note that reaction (iii) is analogous to the formation of GSAO from BRAO and GSH.
  • a nucleophile is TR n :
  • nucleophile HTR n where the nucleophile is TR n -
  • Z is selected from the group consisting of 0, S, NR, or +N(R)(R').
  • hydrophilic amine compounds can be prepared according to the general scheme outlined below which has been exemplified using BRAO in the final step and wherein X is a halogen or other suitable leaving group.
  • glutathione may be reacted with BRAO under conditions favourable to the formation of a covalent bond between the free thiol of glutathione and the chemical entity to which the arsenoxide is attached. Reactions involving nucleophilic attack by the glutathione thiol will, in general, require alkaline conditions.
  • Electrophilic attack of some reactive species on the glutathione sulfur atom may be carried out; in general this would likely require acidic conditions. Suitable modifications will be apparent to those of skill in this art.
  • a person skilled in this art would recognise that the invention also provides for the compounds of the invention in any state of ionisation, for example acid salt, zwitterionic uncharged, zwitterionic anion, dianion.
  • GSAO-B a biotin-linked derivative of GSAO, according to the following formula (IX):
  • n 1 or 2.
  • Example 1 (a) A method of synthesis of GSAO-B is provided in Example 1 (a) and illustrated in Figure 7.
  • R is any desired modifying group.
  • R may be selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, carboxy, alkoxy, alkyl, and aryl.
  • a compound when determining whether a compound was a modifier of at least one protein tyrosine phosphatase selected from the group consisting of: PTP- PEST and PTP-1 B, the uptake into endothelial cells of a labelled substantially cell-membrane impermeable arsenoxide compound, and subsequent effect on these protein tyrosine phosphatases was monitored.
  • the compound was GSAO labelled as 3 H-GSAO.
  • Endothelial cells may be incubated with GSAO for a period of time, typically with 10-100 ⁇ M concentration for 8 to 72 hours.
  • the cells are then immunostained for phosphotyrosine.
  • incubation with GSAO resulted in contraction of the cells and hyperphosphorylation of tyrosine residues in focal adhesion proteins.
  • the hyperphosphorylated proteins may be identified by Western blotting and immunoprecipitation. For example, the extent of tyrosine phosphorylation of two proteins with molecular masses of -120 and -70 kDa was increased by incubation with GSAO. The molecular masses of these proteins correspond to those of FAK and paxillin.
  • FAK and paxillin were immunoprecipitated from control and GSAO-treated endothelial cells. Treatment with GSAO resulted in -1.5- and 3-fold increase in tyrosine phosphorylation of FAK and paxillin, respectively.
  • Tyrosine phosphorylated FAK may be prepared and used as a substrate for PTPases in endothelial cell lysate. For example, dephosphorylation of FAKpTyr was inhibited by GSAO.
  • endothelial cells may be incubated with GSAO and the lysate tested for PTPase activity using FAKpTyr as the substrate. For example, GSAO-treated cells had -10% of the FAKpTyr dephosphorylation activity of untreated cells.
  • the identity of the PTPases that are being inhibited by GSAO in endothelial cells may be determined by incubating endothelial cell lysate with a biotinylated GSAO, immunoprecipitating individual PTPases and blotting with streptavidin-peroxidase to detect incorporation of GSAO. Specific binding can be determined by incubating with GSAO-biotin in the absence or presence of 1 mM 2,3-dimercaptopropanol (DMP). DMP is a small dithiol that competes for binding of GSAO- biotin to protein dithiols. For example, PTP-PEST bound specifically to GSAO-biotin. SHP2 and PTEN did not bind GSAO-biotin.
  • DMP 2,3-dimercaptopropanol
  • the present invention also relates to processes for the identification of compounds as effective modifiers of protein tyrosine phosphatases selected from the group consisting of: PTP- PEST and PTP-1 B, in particular inhibitors of protein tyrosine phosphatases selected from the group consisting of: PTP-PEST and PTP-1 B.
  • the present invention also relates to compounds (modifiers), in particular, inhibitors which are capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and which are preferably detected in accordance with the screening processes set out herein, used alone or together with a pharmaceutically acceptable carrier, adjuvant and/or diluent in methods for the modification of angiogenesis and/or the treatment of angiogenesis dependent disease.
  • salts of the compounds used in the present invention will be pharmaceutically acceptable salts; although other salts may be used in the preparation of the inventive compound or of the pharmaceutically acceptable salt thereof.
  • salt those salts which, within the scope of sound medical judgement, are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio, Pharmaceutically acceptable salts are well known in the art.
  • suitable pharmaceutically acceptable salts of the compounds useful in the present invention may be prepared by mixing a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, phosphoric acid, acetic acid, oxalic acid, carbonic acid, tartaric acid, or citric acid with the compounds of the invention.
  • a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, methanesulfonic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, phosphoric acid, acetic acid, oxalic acid, carbonic acid, tartaric acid, or citric acid.
  • Representative acid addition salts include acetate, adipate, alginate, ascorbate, asparate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesuIfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pe
  • alkali or alkaline earth metal salts include sodium, lithium potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Also included within the scope of compounds used in the present invention are prodrugs.
  • prodrugs will be functional derivatives of the compounds of the present invention which are readily converted in vivo to the required compounds of the present invention as described herein. Typical procedures for the selection and preparation of prodrugs are known to those of skill in the art and are described, for instance, in H. Bundgaard (Ed), Design of Prodrugs, Elsevier, 1985.
  • the compounds or pharmaceutical compositions used in the present invention should provide a quantity of the compound sufficient to effectively treat the patient.
  • One skilled in the art would be able, by routine experimentation, to determine an effective, non-toxic amount of the compounds or pharmaceutical compositions used in the invention which would be required to treat or prevent the disorders and diseases.
  • an effective dosage is expected to be in the range of about 0.0001 mg to about 1000mg per kg body weight per 24 hours; typically, about 0.001 mg to about 750mg per kg body weight per 24 hours; about 0.01 mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 250mg per kg body weight per 24 hours; about 1.0mg to about 250mg per kg body weight per 24 hours.
  • an effective dose range is expected to be in the range about 1.Orng to about 200mg per kg body weight per 24 hours; about 1.Omg to about 100mg per kg body weight per 24 hours; about 1.0mg to about 50mg per kg body weight per 24 hours; about 1 ,0mg to about 25mg per kg body weight per 24 hours; about 5.0mg to about 50mg per kg body weight per 24 hours; about 5.0mg to about 20mg per kg body weight per 24 hours; about 5.0mg to about 15mg per kg body weight per 24 hours.
  • an effective dosage may be up to about 500mg/m2.
  • an effective dosage is expected to be in the range of about 25 to about ⁇ OOmg/m 2 preferably about 25 to about 350mg/m 2 , more preferably about 25 to about 300mg/m2 still more preferably about 25 to about 250mg/m 2 , even more preferably about 50 to about 250mg/m2, and still even more preferably about 75 to about 150mg/m2.
  • an effective dosage is in the range of about 0.0001 mg to about 100 mg GSAO per kg body weight per 24 hours, preferably about 0.001 mg to about 100 mg GSAO per kg body weight per 24 hours, more preferably about 0.01 mg to about 50 mg GSAO per kg body weight per 24 hours, even more preferably about 0.1 mg to about 20 mg GSAO per kg body weight per 24 hours, even more preferably still about 0.1 mg to about 10 mg GSAO per kg body weight per 24 hours.
  • the treatment would be for the duration of the condition.
  • the optimal quantity and spacing of individual dosages of a compound of the present invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the nature of the particular vertebrate being treated. Also, such optimum conditions can be determined by conventional techniques. It will also be apparent to one of ordinary skill in the art that the optimal course of treatment, such as, the number of doses of the compound of the present invention given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. Whilst the compounds used in the present invention may be administered alone, it is generally preferable that the compound be administered as a pharmaceutical composition/formulation. In general pharmaceutical formulations of the present invention may be prepared according to methods which are known to those of ordinary skill in the art and accordingly may include a pharmaceutically acceptable carrier, diluent and/or adjuvant.
  • the carriers, diluents and adjuvants must be "acceptable” in terms of being compatible with the other ingredients of the formulation, and not deleterious to the recipient thereof.
  • Examples of pharmaceutically and veterinarily acceptable carriers or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols,
  • the pharmaceutical composition of the invention comprises an effective amount of a compound identified using the methods of the invention, together with a pharmaceutically acceptable carrier, diluent and/or adjuvant as shown in Example 4.
  • compositions of the invention may be administered by standard routes.
  • the compositions may be administered by the topical, transdermal, intraperitoneal, intracranial, intracerebroventricular, intracerebral, intravaginal, intrauterine, oral, rectal or parenteral (e.g., intravenous, intraspinal, subcutaneous or intramuscular) route.
  • the compositions of the invention may be in the form of a capsule suitable for oral ingestion, in the form of an ointment, cream or lotion suitable for topical administration, in a form suitable for delivery as an eye drop, in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation.
  • compositions of the invention may also be administered in the form of liposomes.
  • Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used.
  • the formulations of the present invention in liposome form may contain, in addition to a compound of the present invention, stabilisers, preservatives, excipients and the like.
  • the preferred lipids are the phospholipids and the phosphatidylcholines (lecithins), both natural and synthetic.
  • non-toxic parenterally acceptable diluents or carriers can include, Ringer's solution, isotonic saline, phosphate buffered saline, ethanol and 1 ,2-propylene glycol.
  • suitable carriers, diluents, excipients and adjuvants for oral use include peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, mannitol, gelatine and lecithin.
  • these oral formulations may contain suitable flavouring and colourings agents.
  • the capsules When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration of the capsule.
  • Adjuvants typically include emollients, emulsifiers, thickening agents, preservatives, bactericides and buffering agents.
  • Solid forms for oral administration may contain binders acceptable in human and veterinary pharmaceutical practice, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents.
  • Suitable binders include gum acacia, gelatine, corn starch, gum tragacanth, sodium alginate, carboxymethylcellulose or polyethylene glycol.
  • Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine.
  • Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar.
  • Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate.
  • Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring.
  • Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten.
  • Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulfite.
  • Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc.
  • Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
  • Liquid forms for oral administration may contain, in addition to the above agents, a liquid carrier.
  • suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides, or mixtures thereof.
  • Suspensions for oral administration may further comprise dispersing agents and/or suspending agents, Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, poly-vinyl-pyrrolidone, sodium alginate or acetyl alcohol. Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono- or di-oleate, -stearate or -laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate, and the like.
  • the emulsions for oral administration may further comprise one or more emulsifying agents.
  • Suitable emulsifying agents include dispersing agents as exemplified above, or natural gums such as guar gum, gum acacia or gum tragacanth.
  • topical formulations of the present invention comprise an active ingredient together with one or more acceptable carriers, and optionally any other therapeutic ingredients.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of where treatment is required, such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions. These may be prepared by dissolving the active ingredient in an aqueous solution of a bactericidal and/or fungicidal compound and/or any other suitable preservative, and optionally including a surface active compound. The resulting solution may then be clarified by filtration, transferred to a suitable container and sterilised. Sterilisation may be achieved by: autoclaving or maintaining at 90°C-100°C for half an hour, or by filtration, followed by transfer to a container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those described above in relation to the preparation of drops.
  • Lotions or liniments for application to the skin may also include an compound to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturiser such as glycerol, or oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application.
  • the basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, com, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogols.
  • the formulation may incorporate any suitable surface active compound such as an anionic, cationic or non-ionic surface active such as sorbitan esters or polyoxyethylene derivatives thereof.
  • suitable surface active compound such as an anionic, cationic or non-ionic surface active such as sorbitan esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • compositions for parenteral administration will commonly comprise a solution of a compound of the present invention or a cocktail thereof dissolved in an acceptable carrier, such as water, buffered water, 0.4% saline, and 0.3% glycine etc, wherein such solutions are sterile and relatively free of particulate matter.
  • an acceptable carrier such as water, buffered water, 0.4% saline, and 0.3% glycine etc
  • parenterally administrable compositions are apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference herein.
  • compositions of the invention may also be administered in the form of liposomes.
  • Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used.
  • the formulations of the present invention in liposome form may contain, in addition to a compound of the present invention, stabilisers, preservatives, excipients and the like.
  • the preferred lipids are the phospholipids and the phosphatidylcholines (lecithins), both natural and synthetic.
  • the present invention also relates to the use of compounds (modifiers), in particular, inhibitors of protein tyrosine phosphatases, wherein the protein tyrosine phosphatases are selected from the group consisting of: PTP-PEST and PTP-1 B, used alone or in a pharmaceutical formulation, for the treatment of disease.
  • the invention relates to a method of inhibiting or stimulating angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier, in the form of an inhibitor or stimulator of these enzymes, or a therapeutically effective amount of a pharmaceutical composition comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • a pharmaceutically acceptable carrier, adjuvant and/or diluent comprising at least one of said modifiers together with a pharmaceutically acceptable carrier, adjuvant and/or diluent.
  • the invention also relates to methods of inhibiting or stimulating angiogenesis in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering to the vertebrate a therapeutically effective amount of at least one modifier of these protein tyrosine phosphatases, or a pharmaceutical composition comprising at least one modifier.
  • these compounds can be used in the treatment of an angiogenesis dependent disease in a vertebrate.
  • the invention relates to methods of treating an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering a therapeutically effective amount of at least one compound capable of inhibiting the activity of at least one of said protein tyrosine phosphatases.
  • the present invention is useful for the treatment of disorders which may be grouped into broad categories such as the following: angiogenesis-dependent diseases, cellular proliferative diseases, inflammatory disorders, auto-immune diseases, blood vessel diseases, thrombosis, viral infection, and cancer.
  • the agents capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, or pharmaceutical formulations thereof may be useful for the treatment of angiogenesis-dependent diseases, such as cancer, hemangioma, arteriovenous malformations, arthritis, Osier-Weber Syndrome, complicated atherosclerotic plaques, psoriasis, corneal graft neovascularization, pyrogenic granuloma, delayed wound healing, retrolental fibroplasia, diabetic retinopathy, scleroderma, granulations, angiofibroma, neovascular glaucoma, trachoma, hemophilic joints, hypertrophic scars, or gastric ulcers.
  • angiogenesis-dependent diseases such as cancer, hemangioma, arteriovenous malformations, arthritis, Osier-Weber Syndrome, complicated atherosclerotic plaques, psoriasis
  • the cancer is selected from the group consisting of carcinogenic tumours, tumours of epithelial origin, such as colo-rectal cancer, breast cancer, lung cancer, head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer; mesenchymal tumours, such as sarcoma; and haemopoietic tumours such as B cell lymphoma.
  • carcinogenic tumours such as colo-rectal cancer, breast cancer, lung cancer, head and neck tumours, hepatic cancer, pancreatic cancer, ovarian cancer, gastric cancer, brain cancer, bladder cancer, prostate cancer and urinary/genital tract cancer
  • mesenchymal tumours such as sarcoma
  • haemopoietic tumours such as B cell lymphoma.
  • the cancer is a haematological tumour. More typically, the cancer is a solid tumour.
  • the agents capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, or pharmaceutical formulations thereof, may also find use in the treatment of human retroviral infections (family retroviridae) including, for example, oncoviral infection such as HTLV-I; Lentiviral infection including HIV-1 and
  • HIV-2 HIV-2; or for the treatment or prevention of Sindbis virus infection.
  • the compounds capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, or pharmaceutical formulations thereof, may also be used in the treatment of inflammatory disorders and/or auto-immune diseases, examples of which include the following: rheumatoid arthritis, seronegative arthritides and other inflammatory arthritides, systemic lupus erythematosus, polyarteritis and related syndromes, systemic sclerosis, Sjogren's syndrome and other inflammatory eye disease, mixed connective tissue disease, polymyositis and dermatomyositis, polymyalgia rheumatica and giant cell arteritis, inflammatory joint disease, non-inflammatory arthropathies and soft tissue rheumatism, algodystrophy.
  • inflammatory disorders and/or auto-immune diseases examples of which include the following: rheumatoid arthritis, seronegative arthritides and
  • vascular disease and thrombosis examples include the following: progression of atherosclerosis; cerebrovascular accidents such as transient ischaemic, completed stroke, and after carotid surgery; acute myocardial infarction (primary and secondary); angina; occlusion of coronary artery bypass graft; occlusion following percutaneous transluminal coronary angioplasty; occlusion following coronary stenting; vascular occlusion in peripheral arterial disease; venous thromboembolic disease following surgery, or during pregnancy, or during immobilisation.
  • small vessel disease for which these compounds or pharmaceutical formulation thereof may be ' used in treatment of, include the following: glomerulonephritis; thrombotic thrombocytopenic purpura; the haemolytic uraemic syndrome; placental insufficiency and preeclampsia.
  • agents capable of changing the activity of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B may also find use in the prevention of thrombosis formation in the following situations: artificial/prosthetic vascular shunts and grafts; prosthetic heart valves; cardiopulmonary bypass procedures; haemoperfusion and haemodialysis.
  • the compounds used in the invention may be used in combination with other known treatments, such as surgery and/or therapeutic agents, including chemotherapeutic or radiotherapeutics.
  • these compounds when used in the treatment of solid tumours, these compounds may be administered with chemotherapeutic agents such as: adriamycin, taxol, fluorouricil, melphalan, cisplatin, alpha interferon, COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methortrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PROMACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, prednisone and procarbazin
  • chemotherapeutic agents include alkylating agents such as nitrogen mustards including mechloethamine, melphan, chlorambucil, cyclophosphamide and ifosfamide; nitrosoureas including carmustine, lomustine, semustine and streptozocin; alkyl sulfonates including busulfan; triazines including dacarbazine; ethyenimines including thiotepa and hexamethylmelamine; folic acid analogues including methotrexate; pyrimidine analogues including 5-fluorouracil, cytosine arabinoside; purine analogues including 6-mercaptopurine and 6-thioguanine; antitumour antibiotics including actinomycin D; the anthracyclines including doxorubicin, bleomycin, mitomycin C and methramycin; hormones and hormone antagonists including tamoxifen and cortiosteroids and
  • the vertebrate is selected from the group consisting of human, non-human primate, murine, bovine, ovine, equine, caprine, leporine, avian, feline and canine. More typically, the vertebrate is human, non-human primate or murine. Even more typically, the vertebrate is human.
  • the present invention also provides a method of diagnosing an angiogenesis dependent disease in a vertebrate, wherein said angiogenesis is dependent on an action of at least one protein tyrosine phosphatase selected from the group consisting of: PTP-PEST and PTP-1 B, and wherein said method comprises administering a diagnostically effective amount of at least one inhibitor of these enzymes, and assessing clinical improvement in signs and symptoms of said disease in said vertebrate.
  • therapeutic challenge with at least one protein tyrosine phosphatase of the invention is an important diagnostic tool for suspected angiogenesis dependent disease, especially when considered together with other aspects of angiogenesis dependent disease.
  • Examples 2(f)-2(i) relating to clinical treatment of angiogenesis dependent disease exemplify the feasibility of diagnosing an angiogenesis dependent disorders using inhibitors of protein tyrosine phosphatases.
  • Bromoacetyl bromide (15 mL, 34.76 g, 172.1 mmol) was diluted in dichloromethane (50 mL) and approximately half of the dichloromethane solution was added carefully to the cold aqueous solution. The mixture was cautiously shaken, with frequent venting to avoid excessive build up of pressure. After 1 to 2 mins, the evolution of carbon dioxide had subsided, and more vigorous shaking was undertaken. The remaining portion of bromoacetyl bromide was carefully added and the procedure repeated. When the reaction was over, the solution was found to be pH 7. The lower dichloromethane layer was discarded, and the aqueous layer transferred to a 1 L flask and carefully acidified by dropwise addition of 98% sulfuric acid.
  • BRAA Into a 3-necked 500 mL round-bottomed flask was placed BRAA (12.15 g, 36 mmol). The solid was dissolved with swirling in a mixture of methanol (75 mL) and hydrobromic acid (48%, 75 mL), giving a transparent yellow solution. The solution was filtered to remove residual solids. Sodium iodide (0.20 g, 1.3 mmol) was added as a catalyst, whereupon the colour of the solution darkened to orange-brown, then sulfur dioxide gas was slowly (ca. 2 bubbles per second) passed through the stirred solution for approximately 2.5 hours. The resultant white precipitate was collected using a B ⁇ chner funnel, giving the product (17.43 g) as a damp white solid.
  • DMSO (10 mL) was deoxygenated by passing a stream of nitrogen gas through it for a few minutes, and used to dissolve BRAO.XH2O (1.00 g, 2.48 mmol active arsenoxide).
  • Glutathione (1.15 g, 3.74 mmol, 1.5 eq) was dissolved in 0.5 M bicarbonate buffer, pH 9.6 (35 mL), and added to the solution of BRAO.xH ⁇ O in DMSO.
  • the total volume was made up to 50 mL with 0.5 M bicarbonate buffer, and the solution gently agitated at room temperature overnight.
  • Cautious neutralisation with 37% hydrochloric acid, followed by lyophilisation gave a white powdery product, which could be dissolved in water leaving no residual solid.
  • the active arsenoxide concentration of the resultant solution was found to be 49.6 mM.
  • the product was purified using gel-filtration (P-2 Gel extra fine, 1.8 kDa cutoff, 50 g) on a 130 mL column, using 20 mM Hepes, 0.14 M NaCl, 1 mM EDTA, pH 7.4 buffer as the eluant at a flow rate of 0.10 mL/min. A total of 144 mL was collected (72 fractions of 2 mL) and monitored by UV ( ⁇ 214nm). Four peaks, A, B, C and D, were resolved. Peaks B and C showed activity in the DTNB/DMP assay (see below), and were assigned as GSAO and unreacted BRAO, respectively.
  • Peaks A and D were tentatively assigned as the oxidation products GSAA and BRAA (the oxidation product of BRAO), respectively. Unreacted glutathione was also detected (using DTNB) in the fractions corresponding to Peak A. The fractions corresponding to peak B were combined and deoxygenated with nitrogen gas to give a solution of GSAO (15 mM, approximately 12 mL).
  • GSAA 4-(A/-(S-qlutathionylacetyl)amino)phenylarsonic acid
  • the product was purified by gel-filtration on a 570 mL column (2.5 x 117 cm) of Bio-Gel P-2 extra fine (BioRad, Hercules, CA) using deionised water as the eluant at a flow rate of 0.1 mL per min.
  • the product (GSAA) eluted from the column in a position corresponding to Peak A in the purification of GSAO.
  • GSAO GSAO (0.13 g) was dissolved in O. ⁇ M sodium bicarbonate buffer ( ⁇ mL, pH 8, ⁇ ) and the concentration of active arsenical in the resultant solution was determined to be 39 mM.
  • the buffered arsenical solution (4.2 mL, containing 165 ⁇ mol active arsenical) was added to a solution of biotin-XX, SE (100 mg, 176 ⁇ mol) in DMSO (1 mL), the mixture inverted a few times and then incubated at 4°C for 4 hours.
  • Glycine (17.5 mg, 233 ⁇ mol) was added and the mixture kept at 4°C overnight.
  • the concentration of trivalent arsenical in the GSAO-B product was determined to be 31 mM and the solution was used without further modification.
  • the arsenicals were reconstituted to concentrations of -50 mM in phosphate buffered saline (PBS) containing 100 mM glycine, sterile filtered and stored at 4°C in the dark until use.
  • PBS phosphate buffered saline
  • the glycine slows the oxidation of GSAO to GSAA.
  • the active concentration of GSAO was measured by titrating the GSAO with 2,3-dimercaptopropanol and measuring the remaining free thiols with 5, ⁇ '-dithiobis(2-nitrobenzoic acid) (Donoghue et al., 2000). There was no significant loss in the active concentration of stock solutions of GSAO for at least 6 weeks when stored under these conditions.
  • 3 H-GSAO was prepared as described for GSAO using glycine-2- 3 H-glutathione (NEN, Boston, MA) in place of unlabelled glutathione.
  • GSCA was prepared by coupling 4-(N-(bromoacetyl)amino)benzoic acid to reduced glutathione.
  • 4-Aminobenzoic acid 13.04 g, 96.1 mmol
  • sodium carbonate 20.32 g, 191.7 mmol
  • water 200 mL
  • Bromoacetyl bromide 15 mL, 172.5 mmol
  • dry dichloromethane 35 mL
  • the mixture was stirred at room temperature for 1 hour, and then left for 3 hours until the precipitate had settled.
  • the clear ethanolic solution was decanted until -300 mL were left, and then this was swirled and centrifuged at 2000g for 5 min.
  • the product was washed by re-suspending in fresh absolute ethanol and centrifuged again. The washing was repeated two more times, and the final suspension was dried to a white solid by rotary evaporation.
  • Monoclonal antibodies that recognize phosphotyrosine (PY20), paxillin, PTP-1 B, SHP2 and PTEN were obtained from Transduction Laboratories, Lexington, KY.
  • Rabbit anti-FAK and peroxidase-coupled anti-phosphotyrosine (PT66) polyclonal antibodies were from Sigma, St. Louis, MO.
  • Rabbit polyclonal antiserum that recognizes human PTP-PEST was a gift from Michael Schaller (Shen et al,, 1998), Peroxidase-coupled anti-mouse and anti-rabbit IgG and fluorescein- coupled anti-mouse IgG were obtained from Dako, Carpinteria, CA, Peroxidase-coupled avidin was from Molecular Probes, Eugene, OR.
  • Dulbecco's Modified Eagle's Medium was from JHR Bioscience, Lenexa, KS; MCDB-131 medium, epidermal growth factor and trypsin/EDTA from Gibco BRL, Gaithersburg, MD; fetal calf serum (FCS) from Intergen, Purchase, NY; bovine calf serum (BCS) from HyClone, Logan, UT; Glutamine Pen-Strep from Irvine Scientific, Santa Ana, VA; FGF-2 from Genzyme, Cambridge, MA; VEGF from Genzyme, Cambridge, MA; and hydrocortisone from Sigma, St. Louis, MO. Adherent cells were counted electronically or stained with methylene blue and counted.
  • FCS fetal calf serum
  • BCS bovine calf serum
  • Adherent cells were counted electronically or stained with methylene blue and counted.
  • Protein samples were electrophoresed on 8-16% gradient SDS-polyacrylamide gels (SDS- PAGE) (Gradipore, Sydney) and transferred to polyvinyldiethylene fluoride (Millipore, Bedford, MA).
  • SDS- PAGE gradient SDS-polyacrylamide gels
  • PBS containing 0.05% Tween 20 and 5% skim milk powder was used for blocking of all membranes except for those to be probed with PT66-peroxidase, which were blocked with PBS/Tween 20 containing 1 % BSA.
  • PT66-peroxidase was diluted 1 :5000, while avidin-peroxidase and anti-paxillin and anti-FAK antibodies were diluted 1 :2000.
  • Blots were developed using ECL enhanced chemiluminescence (NEN, Boston, MA). Densitometry was performed with Molecular Dynamics ImageQuant v3.3 software.
  • PTPases were immunoprecipitated from cell lysates in 1% Triton X lysis buffer (10 mM Tris pH 7,4, 150 mM NaCl, 2 mM EDTA, 1 % (v/v) Triton X-100, 50 Og.mL 4-(2- aminoethyl)-benzenesulfonylfluoride, 10 ⁇ g.mL- 1 leupeptin, 1 ⁇ M aprotinin, 1 ⁇ g.mL- 1 pepstatin A).
  • Proteins were immunoprecipitated from the lysate by adding 10 ⁇ g.mL- 1 antibody and 1 :20 (v/v) Protein-G Sepharose (Amersham Pharmacia, Uppsala, Sweden), and incubating the lysate for 4 h at 4°C with agitation. The beads were then washed twice with lysis buffer, resuspended in SDS- PAGE buffer and stored at -20°C until use.
  • Phosphorylated FAK was prepared by treating -10 7 HMEC-1 with 10 ⁇ M PAO for 30 min. Cells were lysed in 1 ml RIPA buffer for 30 min at 4 °C, scraped into an eppendorf tube and the lysate was clarified at 14000 rpm for ⁇ min. FAK was immunoprecipitated as described above, aliquoted and stored at -20°C until use. To assess the affect of GSAO on phosphatase activity in whole-cell lysates, ⁇ O ⁇ g HMEC-1 lysate in 1% Triton X lysis buffer was pre-incubated with GSAO for 10 min at 37°C.
  • the lysate was then added to the FAK immunoprecipitates and incubated for a further 90 min at 37°C with agitation.
  • the reaction tubes were then transferred to ice, washed twice with lysis buffer, resuspended in SDS-PAGE buffer and stored at -20°C until use.
  • To asses the phosphatase activity in lysates of GSAO-treated cells ⁇ x 10 5 HMEC-1 in a 6-well plate were treated with GSAO, washed twice with PBS and lysed in 1 % Triton X lysis buffer.
  • FAK immunoprecipitates were incubated with ⁇ O ⁇ g lysate for 90 min at 37°C with agitation.
  • Treated cells were washed twice with PBS, fixed for 10 min with 3.7% formaldehyde in PBS, permeabilized for ⁇ min with 3.7% formaldehyde/0.1% Triton X-100 in PBS, then washed twice for 16 min with PBS containing 1 % BSA. Fixed cells were incubated overnight at 4°C with a 1 :100 dilution of mouse anti-phosphotyrosine antibody, washed twice and incubated for 1 h at room temperature with a mixture of 1 :20 fluorescein-conjugated anti-mouse-lgG antibody.
  • the stained cells were washed three times with PBS and mounted in VectaShield antifade agent (Vector Laboratories, Buriingame, CA). Micrographs were taken at 600 ⁇ magnification using an Olympus BX60 microscope with BX-FLA fluorescence, and a Diagnostic Instruments Spot Digital Camera and v 2.2 software (Sterling Heights, Ml).
  • mice Female 7 to 9 week old SCID or C57BI6/J mice were used (Massachusetts General Hospital, Boston, MA). Mice were held in groups of 3 to 5 at a 12 hour day and night cycle and were given animal chow and water ad libidum. Mice were anesthetized by inhalation of isoflurane, the dorsal skin shaved and cleaned with ethanol, and a suspension of 2.6 x 10 6 BxPC-3, AsPc-1 , HT1080 or LLC cells in 0.2 mL of PBS or saline for LLC cells was injected S.C. in the proximal midline, LLC cells were prepared according to O'Reilly et al. (1994). Tumor volume was calculated using the relationship, a.b 2 .0.62, where a is the longest and b the shortest diameter.
  • Example 1(1) Immunohistochemistry Tumors were fixed in Buffered Formalde-Fresh (Fisher Scientific, Fair Lawn, NJ), embedded in paraffin and ⁇ ⁇ m thick sections were cut and placed on glass slides. Sections were stained with haematoxylin and eosin or for CD31 , PCNA (Holmgren et al. 1996) or fragmented DNA (Gavrielli et al., 1992). Microvessels were counted in 3 tumors, including the smallest and largest, from the control and treatment groups and the density was graded in the most active areas of neovascularisation according to Weidner et al. (1991 ).
  • the proliferative index was estimated by the percentage of cells scored under 400 ⁇ magnification. A minimum of 1000 cells was counted in two separate sections. The apoptotic index was estimated by the percentage of cells scored under 400x magnification. A minimum of 1500 cells was counted in two separate sections.
  • Example 2 Results
  • PAO and GSAO are shown in Figure 1A. Coupling PAO to reduced glutathione decreased the cytotoxicity for endothelial cells by -2,000-foId.
  • Adherent bovine aortic endothelial (BAE) cells were incubated with increasing concentrations of PAO, GSAO or GSAA for 24 h and the number of adherent cells remaining was measured (Figure 1B). The IC50 for cell viability was -25 nM for PAO and -60 ⁇ M for GSAO. The control GSAA did not significantly affect BAE viability up to a concentration of 0.5 mM.
  • HMEC-1 human dermal microvascular endothelial cells
  • HMEC-1 primary human umbilical vein endothelial cells
  • GSAO GSAO with closely-spaced dithiols of certain proteins on the endothelial cell-surface and the affects of GSAO on cell viability by blocking endothelial cell-surface thiols with either 3-(N-maleimidylpropionyl)biocytin (MPB) or 5,5'- dithiobis(2-nitrobenzoic acid) (DTNB) prior to incubation with GSAO was considered.
  • MPB 3-(N-maleimidylpropionyl)biocytin
  • DTNB 5,5'- dithiobis(2-nitrobenzoic acid)
  • the maleimide moiety of MPB interacts rapidly (second order rate constant of -10 4 M- 1 s- 1 at neutral pH) and irreversibly with accessible protein thiols, whilst DTNB interacts rapidly but reversibly with protein thiols (Jiang et al., 1999).
  • GSAO interacts with a subset of the MPB or DTNB-labeled proteins (Donoghue et al., 2000).
  • Adherent HMEC-1 were incubated with either 10 or 100 ⁇ M MPB or DTNB prior to addition of GSAO and cultured for 24 h. The number of adherent cells remaining was measured ( Figure 1 C). Pre-treatment with either MPB or DTNB did not significantly change the affect of GSAO on cell viability.
  • HMEC-1 Adherent HMEC-1 were incubated with GSAO or PAO and samples of the cells were resolved on SDS-PAGE, transferred to PVDF membrane and blotted for phosphotyrosine.
  • the molecular masses of these proteins correspond to those of FAK and paxillin.
  • Incubation of HMEC-1 with GSAA did not change the pattern or intensity of tyrosine phosphorylated proteins (not shown).
  • FAK and paxillin were immunoprecipitated from control and GSAO-treated HMEC-1. Treatment with GSAO resulted in elevated tyrosine phosphorylation of both and FAK and paxillin
  • Tyrosine phosphorylated FAK was prepared in HMEC-1 by incubation with PAO and collected by immunoprecipitation.
  • the FAKpTyr was used as a substrate for PTPases in endothelial cell lysate.
  • Inhibition of dephosphorylation of FAKpTyr by vandate, PAO or GSAO was measured ( Figure 2D). As anticipated, both vanadate and PAO inhibited FAKpTyr dephosphorylation.
  • GSAO also inhibited FAKpTyr dephosphorylation and the inhibition was concentration-dependent. Incubation with 2 ⁇ M GSAO resulted in -50% inhibition of PTPase activity. Similar results were obtained using phosphorylated paxillin in place of FAKpTyr (not shown).
  • GSAO-biotin To identify which of the PTPases were interacting with GSAO in endothelial cells, a biotin moiety was attached through a spacer arm to the primary amino group of the ⁇ -glutamyl residue of GSAO to produce (4-(A/-(S-(A/-(6-((6-((biotinoyl)amino)hexanoyl)amino)hexanoyl)- glutathionyl)acetyl)amino)phenylarsenoxide (GSAO-biotin). Binding of GSAO-biotin to PTPases was measured by blotting the biotin with streptavidin-peroxidase.
  • Biotinylation of GSAO does not affect its binding to closely-spaced protein thiols (Donoghue et al., 2000). Lysate of HMEC-1 was incubated with 2 ⁇ M GSAO-biotin in the absence or presence of 1 mM 2,3-dimercaptopropanol (DMP). DMP is a small dithiol that competes for binding of GSAO-biotin to protein dithiols. The dissociation constant for binding of DMP to GSAO is -130 nM (Donoghue et al., 2000).
  • PTP- PEST, SHP2 or PTEN were immunoprecipitated from the lysate and blotted with streptavidin- peroxidase (Figure 2F).
  • PTP-PEST bound specifically to GSAO-biotin.
  • SHP2 and PTEN did not bind GSAO-biotin.
  • PTP-1 B is a cytosolic PTPase that interacts with and dephosphorylates p130 Cas (Liu et al, 1996). HMEC-1 lysate was incubated with GSAO-biotin in the absence or presence of DMP and the PTP-1 B was immunoprecipitated and analyzed as described above, PTP-1 B bound specifically to GSAO-biotin ( Figure 2F).
  • GSAO inhibited the proliferation and reduced the viability of BCE cells in a 72 h proliferation assay ( Figures 3A and 3B). In contrast, GSAA had only a marginal affect on proliferation/viability at the highest concentration used, 1 mM, Inhibition of proliferation by GSAO was independent of whether the cells were stimulated with either fibroblast growth factor-2 (FGF-2) ( Figure 3A) or vascular endothelial cell growth factor (VEGF) ( Figure 3B). The IC50 for inhibition of proliferation in response to FGF-2 or VEGF was -0,1 ⁇ M and -0,05 ⁇ M, respectively (Table 1). GSAO also reduced the viability of BCE cells with IC50 values of -0.4 ⁇ M and -2 ⁇ M in the presence of FGF-2 or VEGF, respectively (Table 1).
  • GSAO inhibited proliferation and reduced viability of BAE cells with IC50 values in the same range as for BCE cells (not shown). GSAA did not affect either proliferation or viability. It is noteworthy that the IC50 for inhibition of proliferation of BAE cells was -0.02 ⁇ M when 5% FCS was the mitogen versus -0.2 ⁇ M when 10% FCS was used (Table 1). High micromolar concentrations of GSAO were required to inhibit the proliferation and viability of the human tumor cell lines, BxPC-3 ( Figure 3C) or HT1080 (not shown), murine 3T3 fibroblasts (not shown) and bovine vascular smooth muscle (BVSM) cells (not shown). IC50 values for proliferation and viability were between 15 and 40 ⁇ M (Table 1). GSAA had no significant affect on proliferation or viability of these cells up to a concentration of 1 mM. Table 1. Effects of GSAO on proliferation and viability of cultured cells in a 72 hour oroliferation assay.
  • the IC50 for inhibition of proliferation of cells was calculated as the concentration of GSAO that reduced the extent of proliferation by half in a 72 hr incubation.
  • the IC50 for reduction in viability of cells was calculated as the concentration of GSAO that reduced the cell number by half in a 72 hr incubation.
  • Adherent BAE cells were induced into growth quiescence by incubating with 0.25% FCS for 48 h and the medium was then replaced with either 0.25% or 10% FCS containing either 50 ⁇ M GSAO or 0.5 ⁇ M PAO. The number of adherent cells after 48 h was measured.
  • GSAO did not significantly affect the viability of growth quiescent endothelial cells but • reduced the viability of proliferating endothelial cells by >90%.
  • PAO at a 100-fold lower concentration than GSAO reduced the viability of both growth quiescent and proliferating endothelial cells equally.
  • the rate of uptake of 3 H-GSAO into growth quiescent BAE cells was similar to that for proliferating BAE cells (see Figure 1 E), which implied that the increased toxicity of GSAO for proliferating BAE cells was not a result of increased uptake of GSAO.
  • the chick CAM assay has been used for the detection and analysis of angiogenesis inhibition (Nguyen et al., 1994).
  • GSAO inhibited CAM angiogenesis in a concentration-dependent manner (Figure 4A).
  • Angiogenesis inhibition was defined as avascular zones 48 h after implantation of methylcellulose pellets containing GSAO on the 6-day CAM ( Figure 4B).
  • GSAA up to 60 ⁇ g per pellet had no affects on CAM angiogenesis.
  • mice SCID or C57BI6/J mice.
  • All mice were examined. There was no apparent macroscopic differences between the GSAA or GSAO-treated and untreated mice.
  • the heart, lungs, liver, kidneys, and spleen of the GSAA or GSAO-treated and untreated mice were fixed in formaldehyde, embedded in paraffin, sectioned, stained with haematoxylin and eosin and examined by light microscopy. There was no obvious morphological changes in any of the organs of the treated mice when compared to the organs of untreated mice (not shown).
  • the present invention has targeted PTPases in proliferating endothelial cells with a hydrophilic trivalent arsenical (GSAO).
  • GSAO hydrophilic trivalent arsenical
  • FAK and paxillin focal adhesion proteins
  • Focal adhesions are the points of cell adhesion to the extracellular matrix, where integrins and associated signalling proteins are clustered and interact with the cytoskeleton (Giancotti & Ruoslahti, 1999).
  • the structural and signalling components of focal adhesions propagate signals from the integrins to the cytoskeleton and other intracellular components. Integrin adhesion to extracellular matrix leads to an increase in tyrosine phosphorylation of multiple proteins, including FAK and paxillin (Burridge et al., 1992).
  • FAK colocalizes with integrins in focal adhesions through its C-terminal focal adhesion targeting sequence (Hildebrand et al. 1993). Phosphorylation of FAK leads to recruitment and phosphorylation of downstream targets including the adaptor protein, paxillin (Schaller and Parsons, 1995; Hildebrand et al., 1995). Paxillin becomes phosphorylated on tyrosine in response to integrin-dependent cell adhesion (Bellis et al., 1997). Paxillin interacts with multiple signaling and structural proteins, including PTP-PEST.
  • FAK is hyperphosphorylated in SHP2 null fibroblasts (Yu et al., 1998) and SHP2 dephosphorylates FAK and paxillin in response to insulin-like growth factor I (Manes et al., 1999). PTEN interacts with and dephosphorylates FAK (Tamura et al., 1998).
  • PTP-PEST and SHP2 are expressed in the blood vessel wall (Wright et al., 2000).
  • PTP-PEST was a PTPase that interacted with relevant concentrations of GSAO-biotin in endothelial cell lysate. This result implied that inhibition of PTP- PEST by GSAO was primarily responsible for hyperphosphorylation of FAK and paxillin in proliferating endothelial cells.
  • PTP-PEST in contrast to SHP2 and PTEN, contains an extra cysteine (Cys235) between the catalytic cysteine (Cys231) and the conserved arginine (Arg237) in the active site cleft.
  • GSAO inhibited other endothelial cell PTPases and increased the phosphorylation state of their substrates. These substrates may have been beyond the resolution of the phosphotyrosine Western blot.
  • the experiment favored the detection of changes in the phosphorylation state of FAK and paxillin as these proteins are two of the most abundant substrates for tyrosine kinases in endothelial cells.
  • PTP-1 B which regulates adhesion, focal adhesion formation and migration in fibroblasts (Liu et al, 1998) and interacts with and dephosphorylates p130 Cas (Liu et al, 1996), also bound GSAO-biotin.
  • PAO perturbed other endothelial cell proteins.
  • PAO binds to and inactivates thioredoxin (Donoghue et al., 2000) and lecithin-cholesterol acyltransferase (Jauhiainen et al., 1988) with dissociation constants of 0.45 ⁇ M and -230 ⁇ M, respectively, and inhibits glucose transport (Frost and Lane, 1985) and ubiquitin-dependent protein degradation (Klemperer and Pickart, 1989) with IC50 values of 7 ⁇ M and 25 ⁇ M, respectively.
  • a cytosolic GSAO concentration of -0.08 ⁇ M resulted from 3 days exposure of endothelial cells to 3 ⁇ M 3 H-GSAO, which was sufficient to inhibit PTPase activity. About 5 to 3,000-fold higher concentrations of PAO than GSAO, therefore, were required to inhibit the activities of these other enzymes and processes. This observation implies that the dominant affect of GSAO in endothelial cells was inhibition of PTPase activity.
  • GSAO was a selective inhibitor of proliferating endothelial cells but had little affect on growth quiescent endothelial cells or other cell types.
  • the GSAO IC50 for inhibition of cell proliferation was 150-400-fold lower for microvascular endothelial cells than for tumor cells, vascular smooth muscle cells or fibroblasts.
  • the GSAO IC50 for reduction in viability was 20-100-fold lower for microvascular endothelial cells than for the other cells.
  • Inactivation of PTP-PEST by GSAO is predicted to perturb focal adhesion disassembly and was probably a major contributor to the reduction in endothelial cell proliferation and viability. Focal adhesions form in response to growth factors and the need for anchorage-dependent movement and growth.
  • Focal adhesion assembly and disassembly is predicted to be less frequent in growth quiescent endothelial cells, therefore, which may have accounted for the small affect of GSAO on the viability of these cells.
  • the inhibition of proliferation and reduction in viability of endothelial cells by GSAO in vitro correlated with inhibition of angiogenesis in vivo.
  • GSAO inhibited angiogenesis in the chick CAM and tumor angiogenesis and tumor growth in mice.
  • S.C. administration of GSAO inhibited the rate of growth of both human or murine tumors in immunocompromised or immunocompetent mice, respectively, by 70 to >90%. There was a marked reduction in blood vessel density in the GSAO- treated BxPC-3 tumors but no signs of necrosis.
  • mice No signs or symptoms of toxicity were observed in any of the in vivo experiments.
  • Preliminary studies in mice have shown that GSAO is rapidly excreted in the urine within 6-8 hours of administration and does not appear to accumulate in any organs.
  • GSAO small size (550 Da) and water solubility of GSAO suggested that it may be orally available in drinking water.
  • the rate of growth of human pancreatic carcinoma and murine LLC tumors in mice was suppressed by -50% with oral administration of GSAO.
  • GSAO is the first example of therapeutic intervention of PTPase activity.
  • the compounds used in the present invention may be administered alone, although it is preferable that they be administered as a pharmaceutical formulation.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% by weight, and more typically from 1% to 5% by weight of the formulation, although it may comprise as much as 10% by weight.
  • a typical composition for delivery as a topical cream is outlined below:
  • a typical composition for delivery as a topical lotion is outlined below:
  • the methyl hydroxybenzoate and glycerin are dissolved in 70 ml of the water at 75°C.
  • the sorbitan monolaurate, polysorbate 20 and cetostearyl alcohol are melted together at 75°C and added to the aqueous solution.
  • the resulting emulsion is homogenised, allowed to cool with continuous stirring and the GSAO is added as a suspension in the remaining water. The whole suspension is stirred until homogenised.
  • Example 4(c) - Eye Drop Composition A typical composition for delivery as an eye drop is outlined below:
  • a lubricating agent such as polysorbate 85 or oleic acid
  • a pharmaceutical composition of the present invention for intramuscular injection could be prepared to contain 1 mL sterile buffered water, and 1 mg of GSAO.
  • a pharmaceutical composition for intravenous infusion may comprise 250 ml of o sterile Ringer's solution, and 5 mg of GSAO.
  • a pharmaceutical composition of GSAO in the form of a capsule may be prepared by filling a standard two-piece hard gelatin capsule with 50 mg of GSAO, in powdered form, 100 mg of lactose, 35 mg of talc and 10 mg of magnesium stearate.
  • a pharmaceutical composition of this invention in a form suitable for administration by injection may be prepared by mixing 1% by weight of GSAO in 10% by volume propylene glycol and water. The solution is sterilised by filtration.
  • Example 4(h) - Ointment Composition o A typical composition for delivery as an ointment includes 1 ,0g of GSAO, together with white soft paraffin to 100.0 g, dispersed to produce a smooth, homogeneous product.
  • HMEC-1 Establishment of an immortalized human microvascular endothelial cell line.
  • End ⁇ statin an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
  • pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant d'identifier un composé qui est un modificateur d'angiogenèse. Ce procédé consiste à mettre en contact une cellule ou un extrait cellulaire avec le composé, à déterminer si il y a un changement dans l'activité d'au moins une protéine tyrosine phosphatase choisie dans le groupe comprenant PTP-PEST et PTP-1B, et ainsi à déterminer si ce composé est un modificateur d'angiogenèse.
PCT/AU2002/000848 2001-06-28 2002-06-28 Modification de l'angiogenese par ciblage de proteines tyrosines phosphatases WO2003003011A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR5989A AUPR598901A0 (en) 2001-06-28 2001-06-28 Inhibition of angiogenesis by targeting protein tyrosine phosphatases
AUPR5989 2001-06-28

Publications (1)

Publication Number Publication Date
WO2003003011A1 true WO2003003011A1 (fr) 2003-01-09

Family

ID=3829956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2002/000848 WO2003003011A1 (fr) 2001-06-28 2002-06-28 Modification de l'angiogenese par ciblage de proteines tyrosines phosphatases

Country Status (2)

Country Link
AU (1) AUPR598901A0 (fr)
WO (1) WO2003003011A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379233A1 (fr) * 2001-03-19 2004-01-14 Unisearch Limited Utilisation d'un compose sensiblement impermeable a la membrane cellulaire pour traiter l'arthrite
EP1453525A1 (fr) * 2001-11-08 2004-09-08 Unisearch Limited, University of New South Wales Ciblage selectif de cellules apoptiques
WO2008052279A1 (fr) * 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Composés d'organo-arsénoxydes et leur utilisation
WO2009043114A1 (fr) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Composé d'oxyde d'arsenic et son procédé d'utilisation
US7619000B2 (en) 2002-01-07 2009-11-17 The Texas A&M University System S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
CN102154495A (zh) * 2011-03-14 2011-08-17 浙江省农业科学院 鉴别大豆籽粒中低植酸含量突变基因IPK1-a的分子标记方法和引物
US8796329B2 (en) 2006-09-29 2014-08-05 Ziopharm Oncology, Inc. Method for controlling angiogenesis in animals
WO2016061618A1 (fr) * 2014-10-24 2016-04-28 Newsouth Innovations Pty Limited Ciblage sélectif de plaquettes procoagulantes
US9353152B2 (en) 2002-11-07 2016-05-31 Newsouth Innovations Pty Limited Induction of the mitochondrial permeability transition

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US5965558A (en) * 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
WO1999061467A2 (fr) * 1998-05-21 1999-12-02 Mcgill University Agents interferant avec la liaison de typrosine-phosphatase pest a des domaines de proteines de signalisation en tant qu'inhibiteurs de migration cellulaire et/ou d'adhesion focale
WO2000015258A1 (fr) * 1998-09-11 2000-03-23 Vanderbilt University Modulation de l'activite d'un recepteur de surface des cellules endotheliales dans la regulation de l'angiogenese
EP1046715A1 (fr) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction de la protéine vasculaire endothelial tyrosine phosphatase et le récepteur Tie-2 d'angiopoietine
WO2001012180A2 (fr) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Composes de peroxovanadium comme inhibiteurs de la proteine tyrosine phosphatase (ptp): leurs effets inhibiteurs sur l'angiogenese, la restenose et la production d'endothelines, et leurs effets stimulants sur la reponse immunitaire
WO2001021628A1 (fr) * 1999-09-20 2001-03-29 Unisearch Limited Compose essentiellement impermeable a la membrane cellulaire et son utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US5965558A (en) * 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
WO1999061467A2 (fr) * 1998-05-21 1999-12-02 Mcgill University Agents interferant avec la liaison de typrosine-phosphatase pest a des domaines de proteines de signalisation en tant qu'inhibiteurs de migration cellulaire et/ou d'adhesion focale
WO2000015258A1 (fr) * 1998-09-11 2000-03-23 Vanderbilt University Modulation de l'activite d'un recepteur de surface des cellules endotheliales dans la regulation de l'angiogenese
EP1046715A1 (fr) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction de la protéine vasculaire endothelial tyrosine phosphatase et le récepteur Tie-2 d'angiopoietine
WO2001012180A2 (fr) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Composes de peroxovanadium comme inhibiteurs de la proteine tyrosine phosphatase (ptp): leurs effets inhibiteurs sur l'angiogenese, la restenose et la production d'endothelines, et leurs effets stimulants sur la reponse immunitaire
WO2001021628A1 (fr) * 1999-09-20 2001-03-29 Unisearch Limited Compose essentiellement impermeable a la membrane cellulaire et son utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Characterization of the major protein-tyrosine-phosphatases of human placenta", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 14, 1988, pages 6731 - 6737 *
BURKE T.R. JR., ZHONG-YIN ZHANG: "Protein-tyrosine phosphatases: structure, mechanism and inhibitor discovery", BIOPOLYMERS (PEPTIDE SCIENCE), vol. 47, 1998, pages 225 - 241 *
LEE E.S. ET AL.: "Thioallyl compounds: potent inhibitors of cell proliferation", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1221, 1994, pages 73 - 77 *
TAYLOR S.D. ET AL.: "Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 6, 1998, pages 1457 - 1468 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379233A4 (fr) * 2001-03-19 2005-10-26 Unisearch Ltd Utilisation d'un compose sensiblement impermeable a la membrane cellulaire pour traiter l'arthrite
US7186695B2 (en) 2001-03-19 2007-03-06 New South Innovations Pty Limited Treatment of arthritis with arsenoxide compounds
EP1379233A1 (fr) * 2001-03-19 2004-01-14 Unisearch Limited Utilisation d'un compose sensiblement impermeable a la membrane cellulaire pour traiter l'arthrite
EP1453525A1 (fr) * 2001-11-08 2004-09-08 Unisearch Limited, University of New South Wales Ciblage selectif de cellules apoptiques
EP1453525A4 (fr) * 2001-11-08 2006-03-15 Unisearch Ltd University Of Ne Ciblage selectif de cellules apoptiques
US7619000B2 (en) 2002-01-07 2009-11-17 The Texas A&M University System S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
US9353152B2 (en) 2002-11-07 2016-05-31 Newsouth Innovations Pty Limited Induction of the mitochondrial permeability transition
US8796329B2 (en) 2006-09-29 2014-08-05 Ziopharm Oncology, Inc. Method for controlling angiogenesis in animals
JP2010508245A (ja) * 2006-11-01 2010-03-18 ニューサウス イノベイションズ ピーティーワイ リミテッド 有機アルセノキシド化合物およびその使用
AU2007314076B2 (en) * 2006-11-01 2012-07-19 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
US8268883B2 (en) 2006-11-01 2012-09-18 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
WO2008052279A1 (fr) * 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Composés d'organo-arsénoxydes et leur utilisation
US9765101B2 (en) 2006-11-01 2017-09-19 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
WO2009043114A1 (fr) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Composé d'oxyde d'arsenic et son procédé d'utilisation
CN102154495A (zh) * 2011-03-14 2011-08-17 浙江省农业科学院 鉴别大豆籽粒中低植酸含量突变基因IPK1-a的分子标记方法和引物
WO2016061618A1 (fr) * 2014-10-24 2016-04-28 Newsouth Innovations Pty Limited Ciblage sélectif de plaquettes procoagulantes
US10828275B2 (en) 2014-10-24 2020-11-10 Newsouth Innovations Pty Limited Selective targeting of procoagulant platelets

Also Published As

Publication number Publication date
AUPR598901A0 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
US7674775B2 (en) Substantially cell membrane impermeable compound and use thereof
US9353152B2 (en) Induction of the mitochondrial permeability transition
CN108276490A (zh) 使用BCL-9的安定的α螺旋将癌症中失调WNT信号传递订为目标
US20180148437A1 (en) Novel Ezrin Inhibitors and Methods of Making and Using
WO2003003011A1 (fr) Modification de l'angiogenese par ciblage de proteines tyrosines phosphatases
JP2003514850A (ja) 薬剤を調製するためのインジルビン誘導体の使用
US7186695B2 (en) Treatment of arthritis with arsenoxide compounds
US11306063B2 (en) Heterocyclic naphthoquinones derivatives for use in the treatment of cancers including Cushing disease
Standing et al. Doublecortin‐like kinase 1 is a therapeutic target in squamous cell carcinoma
CN112851558B (zh) 2-氰基非那烯酮类化合物及其在白血病治疗中的应用
Duan et al. Rational design and synthesis of 2, 4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non‐small cell lung cancer
AU778781B2 (en) A substantially cell membrane impermeable compound and use thereof
AU2005201144B9 (en) A substantially cell membrane impermeable compound and use thereof
WO2017211318A1 (fr) Inhibiteur de la topk à effet antitumoral
US9670197B2 (en) Small molecule modifiers of the Hec1-Nek2 interaction in G2/M
TWI725041B (zh) 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
US20250073209A1 (en) COVALENT TARGETING OF RhoA FOR CANCER THERAPY
AU2008200304B2 (en) Induction of the mitochondrial permeability transition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2004109122

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2004113087

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载